Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
Jane E RogersJaffer AjaniPublished in: Current oncology (Toronto, Ont.) (2024)
Gastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth factor receptor-2 (HER-2) represented the single target in GACs for many years, seen in approximately 20% of patients with advanced GAC. Recent advances in management now include the addition of immunotherapy checkpoint inhibition to select front-line advanced GACs. Unfortunately, outcomes remain poor for most patients. We anticipate finding a key to future discoveries in GACs in next-generation sequencing and more targeted approaches. Claudin 18.2 (CLDN18.2) has emerged as a therapeutic target in GACs. CLDN18.2 is reportedly expressed in 14-87% of GACs, and CLDN18.2 is available for monoclonal antibody (mAb) binding as it is expressed on the outer cell membrane. Here, we review the exploration of CLDN18.2 as a target in GACs via the use of zolbetuximab (IMAB362). Zolbetuximab is now under priority FDA review for GACs, and we eagerly await the review outcome.
Keyphrases
- monoclonal antibody
- epidermal growth factor receptor
- end stage renal disease
- squamous cell carcinoma
- endothelial cells
- tyrosine kinase
- newly diagnosed
- ejection fraction
- chronic kidney disease
- dna damage
- advanced non small cell lung cancer
- locally advanced
- cancer therapy
- cell cycle
- copy number
- genome wide
- drug delivery
- insulin resistance
- circulating tumor